Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

PTEN loss reprograms lipid metabolism to modulate venetoclax resistance in acute myeloid leukemia

Mutian Cao, Lizhen Cong, Yujiao Jia et al. Nov 03, 2025 pp. 3268-3268 10.1182/blood-2025-3268

Abstract Acute myeloid leukemia (AML) is an aggressive and biologically heterogeneous hematologic malignancy. It is characterized by the clo...

Treatment of type 1 plasminogen deficiency in women and girls with reproductive tract lesions: Pharmacokinetics and clinical outcomes with plasminogen therapy

Karen Thibaudeau, Per Morten Sandset, Anne Flem Jacobsen et al. Nov 03, 2025 pp. 1310-1310 10.1182/blood-2025-1310

Abstract Background: Type 1 plasminogen deficiency (PLGD-1) is an ultra-rare autosomal recessive disorder affecting approximately 1.6 indivi...

CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma

Yuyang Gao, Mingzhi Zhang Nov 03, 2025 pp. 5877-5877 10.1182/blood-2025-5877

Abstract Objective CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B-cell...

Epidemiology of cancer-associated venous thromboembolism in a nationwide electronic healthrecord database

Barbara Lam, Justine Ryu, Omid Jafari et al. Nov 03, 2025 pp. 4898-4898 10.1182/blood-2025-4898

Abstract Background Prior cancer-associated thrombosis (CAT) epidemiological studies focused on specific populations or single healthcare sy...

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Sankalp Arora, Koji Sasaki, Nicholas Short et al. Nov 03, 2025 pp. 759-759 10.1182/blood-2025-759

Abstract Introduction: Blinatumomab (Blina) is a CD19/CD3 bispecific T-cell engager with demonstrated efficacy in B-cell acute lymphoblastic...

Real-world safety and effectiveness of hetrombopag in patients with primary immune thrombocytopenia

Heng Mei, Fengkui Zhang, Yu Hu Nov 03, 2025 pp. 3034-3034 10.1182/blood-2025-3034

Abstract Introduction: Primary Immune Thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by isolated thrombocy...

Spatial asymmetry of blasts in bone marrow after hematopoietic stem cell transplantation for AML/MDS

Ruowen Wei, Ao Zhang, Moran Wang et al. Nov 03, 2025 pp. 6040-6040 10.1182/blood-2025-6040

Abstract Background Bone marrow (BM) aspiration is essential for monitoring post-transplant relapse in AML/MDS and is typically performed un...

Acute Myeloid Leukemia patients with comorbid hidradenitis suppurativa maintain stable disease during induction therapy–induced neutropenia: A single-center retrospective study

Amruth Alluri, Jason Truong, Yashaswi Guntupalli Nov 03, 2025 pp. 6915-6915 10.1182/blood-2025-6915

Abstract Background: Induction therapy for acute myeloid leukemia (AML) is associated with profound neutropenia, which can predispose patien...

A low-cost Clinical Prediction model for identifying female hemophilia carriers and women and girls with hemophilia (WGH) in central China

Li Zhou, Wan Jiarui, An Xinyu et al. Nov 03, 2025 pp. 1292-1292 10.1182/blood-2025-1292

Abstract Background While hemophilia is traditionally considered an X-linked recessive disorder mainly affecting males, female hemophilia ca...

Identification of factors associated with a high success rate of treatment-free remission in chronic myeloid leukemia: A multicenter study in Taiwan

Ning-Chun Chen, Ming-Chung Kuo, Tung-Huei Lin et al. Nov 03, 2025 pp. 3781-3781 10.1182/blood-2025-3781

Abstract Background and purpose: Treatment-free remission (TFR) has become a goal for chronic myeloid leukemia (CML) patients treated with ty...

Real-world step-up dosing of patients receiving elranatamab for multiple myeloma in Japan

Satoshi Yoshihara, Ariane Faucher, Sarasa MA Johnson et al. Nov 03, 2025 pp. 8143-8143 10.1182/blood-2025-8143

Abstract Background Elranatamab is the first bispecific B-cell maturation antigen (BCMA)-CD3–directed monoclonal antibody approved in Japan...

Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming

Yueyu Dai, Yue Liu, Lingna An et al. Nov 03, 2025 pp. 2334-2334 10.1182/blood-2025-2334

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has been shown remarkable efficacy in the treatment of hematological m...

Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies

Thomas LeBlanc, Amir Ali, Victoria Campbell et al. Nov 03, 2025 pp. 5215-5215 10.1182/blood-2025-5215

Abstract CPX-351 is a therapy approved for newly diagnosed (ND) therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-re...

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Yan Gao, Xue-Ping Li, Xuan-Ye Zhang et al. Nov 03, 2025 pp. 5517-5517 10.1182/blood-2025-5517

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most prevalent aggressive subtype of non-Hodgkin lymphoma, characterized by...

Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm

Patricia Alejandra Flores Pérez, Juan Pablo Capdevila, Karla Mariana Castro Bórquez et al. Nov 03, 2025 pp. 8154-8154 10.1182/blood-2025-8154

Abstract Background Accurate reconstruction of electronic health record (EHR) treatment sequences is essential for leveraging real-world dat...

Unlocking new frontiers in leukemia diagnostics through large language Model–Driven report generation

Vivian Wuerf, Christopher Maier, Benjamin Braun et al. Nov 03, 2025 pp. 2574-2574 10.1182/blood-2025-2574

Abstract Background: Writing of diagnostic reports is a cumbersome and challenging task. Expert knowledge and cross-methodological thinking...

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Jacqueline Barrientos, Michael Doubek, Zsolt Lazar et al. Nov 03, 2025 pp. 3301-3301 10.1182/blood-2025-3301

Abstract Introduction Continuous treatment with a Bruton's tyrosine kinase inhibitor (BTKi) is a standard of care option for patients (pts) w...

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

Masahiro Takeyama, Kenichi Ogiwara, Naoki Ozu et al. Nov 03, 2025 pp. 4847-4847 10.1182/blood-2025-4847

Abstract Introduction Emicizumab prophylaxis reduces bleeding in people with hemophilia A (PwHA), offering hemostatic activity equivalent to...

Thiotepa and busulfan combined with cyclophosphamide conditioning regimen plus maintenance therapy improved the disease-free survival of patients with relapsed/refractory haematologic malignancies after undergoing allogeneic transplantation

Shulian Chen, Rui Cui, Yi He et al. Nov 03, 2025 pp. 5974-5974 10.1182/blood-2025-5974

Abstract Objective: Conditioning regimens are critical for patients with relapsed/refractory (R/R) malignant haematologic diseases. Thiotepa...

AI-assisted diagnosis of paroxysmal nocturnal hemoglobinuria

Adam Bowen, Maha Bayya, Miller Lantis et al. Nov 03, 2025 pp. 4670-4670 10.1182/blood-2025-4670

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated intravasc...

Platelet proteomic signatures reveal neurodegenerative and mitochondrial pathways associated with pain phenotypes in sickle cell disease

Keesha Powell-Roach, Ugochi Ogu, Anandi Krishnan et al. Nov 03, 2025 pp. 2925-2925 10.1182/blood-2025-2925

Abstract Background: Sickle cell disease (SCD) is a complex hematologic disorder marked by chronic pain and neurocognitive impairments. Whil...

Implementation of a next generation sequencing painel for lymphoid malignancies in Brazil: First report of molecular features in a low-middle income country

Andre Meireles, Paloma Resende, Luiz Gustavo Cortes et al. Nov 03, 2025 pp. 7066-7066 10.1182/blood-2025-7066

Abstract Background: The understanding of chronic lymphoproliferative disease has advanced significantly with the incorporation of next-gene...

Targeting early immunologic decline in acquired hemophilia A: A case for prophylactic rituximab

Ranjana Lingutla, Kelly Pan, John Reagan et al. Nov 03, 2025 pp. 6642-6642 10.1182/blood-2025-6642

Abstract Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against factor VIII (FVIII). While immu...

Diagnosing mycosis fungoides using AI powered histologic analysis

Mohamed Sharaf, Marianna Shvartsbeyn, Alessio Giubellino et al. Nov 03, 2025 pp. 2570-2570 10.1182/blood-2025-2570

Abstract Background Mycosis Fungoides (MF) is the most common type of cutaneous T-cell lymphoma. Unfortunately, the diagnosis of MF is chall...

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu et al. Nov 03, 2025 pp. 2124-2124 10.1182/blood-2025-2124

Abstract Background: Although Bruton tyrosine kinase (BTK) inhibitor monotherapy yields an overall response rate (ORR) of 80–90% and prolong...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page